InsiderTrades.com logo
Unveiled: NVIDIA’s "Secret Royalty" Program
From Behind the Markets   |   Ad
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?
Click Here to learn how to get in now >>>

KPRX Insider Trading

Insider Ownership Percentage: 0.94%
Insider Buying (Last 12 Months): $64,388.79
Insider Selling (Last 12 Months): $0.00

Kiora Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Kiora Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kiora Pharmaceuticals Share Price & Price History

Current Price: $3.29
Price Change: ▼ Price Decrease of -0.11 (-3.24%)
As of 11/15/2024 01:00 AM ET

This chart shows the closing price history over time for KPRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold   |   Ad
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.

Kiora Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/10/2024Aron ShapiroDirectorBuy3,000$3.60$10,800.003,000View SEC Filing Icon  
8/19/2024Lisa Walters-HoffertDirectorBuy1,250$3.86$4,825.001,250View SEC Filing Icon  
6/14/2024Eric Joseph DanielsInsiderBuy1,431$5.29$7,569.9911,222View SEC Filing Icon  
6/14/2024Melissa ToscaEVPBuy100$5.25$525.003,979View SEC Filing Icon  
6/13/2024Brian M StremCEOBuy3,000$5.00$15,000.0014,531View SEC Filing Icon  
6/13/2024Erin ParsonsDirectorBuy5,260$4.88$25,668.805,260View SEC Filing Icon  
See Full Table
“This Changes Everything” - Trump Hands Millions Massive IRS Gift
From Colonial Metals   |   Ad
Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…
>> YES! Send Me My FREE Gold Guide!

SEC Filings (Institutional Ownership Changes) for Kiora Pharmaceuticals (NASDAQ:KPRX)

76.97% of Kiora Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KPRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Kiora Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/21/2024Stonepine Capital Management LLC200,000$0.84M0.8%N/A6.856%Search for SEC Filing on Google Icon
8/20/2024Nantahala Capital Management LLC211,110$0.89M0.1%-88.9%7.237%Search for SEC Filing on Google Icon
8/7/2024AIGH Capital Management LLC255,561$1.07M0.3%-88.9%8.761%Search for SEC Filing on Google Icon
7/12/2024Rosalind Advisors Inc.255,555$1.07M0.8%-88.9%8.752%Search for SEC Filing on Google Icon
4/25/2024Rosalind Advisors Inc.2,300,000$1.62M1.5%N/A8.759%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Kiora Pharmaceuticals logo
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Read More on Kiora Pharmaceuticals

Today's Range

Now: $3.29
Low: $3.16
High: $3.38

50 Day Range

MA: $3.52
Low: $3.10
High: $4.04

52 Week Range

Now: $3.29
Low: $3.00
High: $8.98

Volume

34,019 shs

Average Volume

45,703 shs

Market Capitalization

$9.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Kiora Pharmaceuticals?

Kiora Pharmaceuticals' top insider investors include:
  1. Brian M Strem (CEO)
  2. Eric Joseph Daniels (Insider)
  3. Erin Parsons (Director)
  4. Melissa Tosca (EVP)
  5. Aron Shapiro (Director)
  6. Lisa Walters-Hoffert (Director)
Learn More about top insider investors at Kiora Pharmaceuticals.
Unveiled: NVIDIA’s "Secret Royalty" Program
From Behind the Markets   |   Ad
Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?
Click Here to learn how to get in now >>>